Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 13,383

Document Document Title
WO/2021/089790A1
The present invention relates to compounds having a lipid affinity of less than 15% by weight of the compound (such as a logP of -0.75 or less) for use in targeting mitochondria to reduce, inhibit or prevent the formation of mitochondria...  
WO/2021/092332A1
Disclosed are compositions engineered nanovesicles and compositions comprising CD38 inhibitors and methods of using said nanovesicles and compositions to treat an inflammatory liver disease as well as in inhibiting, reducing, or repairin...  
WO/2021/088446A1
A method for staggered powering-on of server hard disks, a device, and a medium. The method comprises: setting the total number of each group of hard disk blocks to be powered on and a time interval between two groups to be powered on; d...  
WO/2021/085232A1
[Problem] Provided is a composition useful for treating and/or preventing neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. [Solution] This composition is for treating and/or preventing neurodegenerative di...  
WO/2021/081634A1
A combination that includes: a flavonoid, for example in an amount from about 0.1 g to about 1.5 g; and one or more of: ascorbic acid, ascorbate, or a combination thereof, for example in an amount from about 0.2 g to about 2.0 g; N-acety...  
WO/2021/084213A1
The present invention relates to the use of neurosporene to protect the skin from the harmful effects of blue light and/or UVA, to promote epidermal regeneration or renewal, and to stimulate wound healing.  
WO/2021/085496A1
Disclosed are an antioxidant agent, an antisaccharification agent, a neurite outgrowth promoter, and a cognitive function improver which contain propolis and gingko leaf extract as active ingredients.  
WO/2021/085906A1
The present invention relates to a mitochondria-targeting compound and a composition comprising same for treating or preventing aging-related diseases. A compound according to one aspect or a pharmaceutically acceptable salt thereof, and...  
WO/2021/087064A1
Methods are provided herein for determining the eligibility of a subject to receive a treatment based on a presence or absence of B- cells in the subject, and subsequently treating the eligible subject with the anti-CD47 treatment in com...  
WO/2021/071159A1
The present invention relates to an antidiabetic, hypotensive, or antioxidant composition comprising a yeast fermentate of Rhynchosia Nulubilis and a method for preparing the composition.  
WO/2021/070184A1
The present invention is directed to a composition comprising phytoene, phytofluene, and zeta carotene, and methods of using the same, such as for reducing collagen loss.  
WO/2021/063075A1
The present invention relates to the technical field of biomedicine, and disclosed are an albiziae cortex lignan compound and an application thereof. The compound prepared by the present invention can effectively treat FFAs-induced lipid...  
WO/2021/063355A1
Provided is a method for constructing food-grade ethanol-degrading Bacillus subtilis recombinant bacteria. The method integrates expression cassettes of two enzyme genes into the genome of Bacillus subtilis by means of double-crossover h...  
WO/2021/056270A1
Senolytic prodrugs are provided, which are designed from a cytotoxic agent, by chemically modifying the cytotoxic agent to incorporate a site cleavable by SA-β-gal following delivery of the prodrug in vivo, to release the active parent ...  
WO/2021/057721A1
Disclosed is a specific antidotal drug for treating paraquat acute poisoning. The main ingredient of the drug is a hydroquinone compound or a pharmaceutically acceptable salt thereof, preferably 9,10-anthrahydroquinone-2,6-disulfonic aci...  
WO/2021/057061A1
Senolytic and anti-inflammatory prodrugs are provided, which are designed from a cytotoxic agent, by chemically modifying the cytotoxic agent to incorporate a site cleavable by SA-β-gal following delivery of the prodrug in vivo, to rele...  
WO/2021/056996A1
Senolytic and anti-inflammatory prodrugs are provided, which are designed from a cytotoxic agent, by chemically modifying the cytotoxic agent to incorporate a site cleavable by SA-β-gal following delivery of the prodrug in vivo, to rele...  
WO/2021/057840A1
Senolytic and anti-inflammatory prodrugs are provided, which are designed from a cytotoxic agent, by chemically modifying the cytotoxic agent to incorporate a site cleavable by SA-β-gal following delivery of the prodrug in vivo, to rele...  
WO/2021/054149A1
A compound represented by R1S(S)nSR2 (R1 and R2 each independently represent a residue obtained by removing one thiol group from a thiol-group-containing compound, and n represents an integer equal to or greater than 1) or a pharmacologi...  
WO/2021/048620A1
The present invention relates to compounds of formula (I) that are capable of modulating, e.g., inhibiting or activating, one or more kinases, especially LRRK2 and/or NUAK1 and/or TYK2 or mutants thereof. The compounds are useful for tre...  
WO/2021/048618A1
The present invention relates to compounds of formula (I) that are capable of modulating, e.g., inhibiting or activating, one or more kinases, especially LRRK2 and/or NUAK1 and/or TYK2 or mutants thereof. The compounds are useful for tre...  
WO/2021/050449A1
Provided herein are compositions and methods of ameliorating the pharmaceutical aversiveness of active pharmaceutical ingredient (API) by administering the API after or substantially simultaneously with a flavone compound.  
WO/2021/043120A1
A compound amino acid dipeptide injection and a preparation method therefor and an application thereof. The compound amino acid dipeptide injection comprises three cavity bags spaced apart from each other and respectively filled with a b...  
WO/2021/039968A1
The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1) [wherein X1 represents CR1 or N, X2 represents CR2 or N, X3 represents CR3 or N, Y represents an optionally ...  
WO/2021/032212A1
Provided are a pharmaceutical composition comprising dasatinib and aspirin and a cartridge or kit thereof and the use thereof. The pharmaceutical composition can down-regulate or eliminate natural aging cells or damaged cells, thereby pr...  
WO/2021/032213A1
Provided in the present invention are an anti-aging medicine D/S having the effect of targeting aging cells in the tissue microenvironment and the use thereof. Dasatinib is used in combination with SRT2104, which has an extremely excelle...  
WO/2021/034943A1
Compositions and methods for in vivo immunoimaging IL-12 as a marker of IL- 12-producing activated antigen presenting cells (APCs) in a subject are provided according to aspects of the present disclosure which include: administering a la...  
WO/2021/034298A1
The present invention has shown that sodium pyruvate formula with calcium, phosphate and magnesium was superior and was synergistic over our standard sodium pyruvate formula in removal of mucus and lung tightness, reduce lung or sinus in...  
WO/2021/029673A1
The present invention relates to a composition for inhibiting the toxicity with respect to nanoparticles and fine particles generated from the environment. Since it has been confirmed that a decrease in intracellular ATP, a decrease in c...  
WO/2021/029347A1
Provided is a novel anticancer drug-decomposing agent which comprises hypochlorous acid as an active ingredient. The anticancer drug-decomposing agent, which is to be used for decomposing an anticancer drug, is a weakly acidic aqueous ...  
WO/2021/025147A1
The purpose of the present invention is to provide a novel use of sulfated hyaluronic acid. The present invention provides a composition for a subject who has been exposed to radiation or who is at a risk of being exposed to radiation, t...  
WO/2021/020362A1
Provided is a compound which has a glucosylceramide synthase-inhibiting activity and is expected to be useful as a prophylactic or therapeutic agent for a lysosomal storage disease (e.g., Gaucher disease, Fabry disease, GM1-gangliosidosi...  
WO/2021/020363A1
Provided is a compound which has a glucosylceramide synthase-inhibiting activity and is expected to be useful as a prophylactic or therapeutic agent for a lysosomal storage disease (e.g., Gaucher disease, Fabry disease, GM1-gangliosidosi...  
WO/2021/021699A1
Provided herein are compounds useful in the prevention or treatment of ferroptosis in a patient, and methods of preventing or treating ferroptosis, or a treating a condition or disease associated with ferroptosis, such as a patient havin...  
WO/2021/012686A1
Disclosed is a naloxone hydrochloride injection and a preparation method therefor. The injection consists of naloxone hydrochloride, sodium chloride, ethylenediamine tetraacetate, hydrochloric acid, a related substance and water, wherein...  
WO/2021/016280A1
The present disclosure provides certain tricyclic compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also provided are pharmaceu...  
WO/2021/012721A1
Disclosed in the present invention are a naphthalenesulfonamide compound, a preparation method, and an application. The naphthalenesulfonamide compound provided by the present invention can interfere with Keap1-Nrf2 binding and activate ...  
WO/2021/014861A1
Provided is a harmful-to-health substance removing agent containing a plant-derived porous carbon material that has a mesopore volume of 0.10 cm3/g or more.  
WO/2021/009384A1
The present invention relates to novel pyrazolone derivatives of the following formula (I): (I) or a pharmaceutically acceptable salt and/or solvate thereof and to a pharmaceutical composition comprising thereof. The present invention al...  
WO/2021/008265A1
An anti-aging soft capsule for menopausal women and a preparation method therefor. The soft capsule is composed of capsule contents and a capsule shell. The capsule contents are prepared from soy isoflavone extract powder, pomegranate se...  
WO/2020/251698A3
The present disclosure is directed at compositions of dimethyl trisulfide (DMTS) suitable for use for treatment of cyanide intoxication. The compositions show particularly useful stability such that the DMTS remains stable for therapeuti...  
WO/2021/007062A1
A process for removing Co2+, Pb2+, Cd2+ and Cr3+ toxins from bodily fluids is disclosed. The process involves contacting the bodily fluid with an ion exchange composition to remove the metal toxins in the bodily fluid, including blood an...  
WO/2021/004463A1
A method for preparing an antioxidative peptide from a peanut meal by employing a high pressure-assisted enzymatic hydrolysis method, comprising the extraction of heat denatured protein in the peanut meal, high-pressure preprocessing, en...  
WO/2021/002359A1
The present inventors have identified antisense oligonucleotides (ASOs) which act on a p53 gene transcription product. By using these relatively short oligonucleotides, the amount of p53 mRNA can be reduced and the expression of the prot...  
WO/2021/000224A1
Disclosed is a method for separation and purification of grape polyphenols by means of a resin, and the method belongs to the technical field of the food industry. The method involves first extracting wine lees using an alkali solution t...  
WO/2020/263995A1
Compounds of Formula I are provided:(I) R1 is -OR5, m is an integer from 0 to 5, n is an integer from 0 to 2, each R2 is independently selected from hydrogen, halogen, and alkyl, R3 is selected from hydrogen, alkyl, cycloalkyl, aryl, hyd...  
WO/2020/262555A1
A side effect reducing agent for a nucleic acid drug that comprises an oligopeptide containing an oligopeptide domain, said oligopeptide domain consisting of 2-40 amino acids and including a structure W that has two or more specific cons...  
WO/2020/259294A1
Disclosed by the present invention is the use of a growth-promoting hormone releasing hormone agonist GHRH-A in preparing an anti-aging medicament. GHRH-A is capable of resisting aging, comprising reducing the positive rate of senescence...  
WO/2020/263075A1
This invention relates to a formulation that reduces oxidative stress in a mammal patient suffering cognitive status, the formulation including: a water content between 89.38o% to 92.93%, ash content o f 0.12% to 0.15%, protein content o...  
WO/2020/255989A1
Provided is a novel compound which is contained in a watermelon young fruit and has an antioxidative effect. A novel compound which is contained in a watermelon young fruit and is represented by formula (1) or (2) has an antioxidative ...  

Matches 1 - 50 out of 13,383